Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Inflation Consequences for the Stock Market, FED Balance Sheet - 24th Oct 21
To Be or Not to Be: How the Evergrande Crisis Can Affect Gold Price - 24th Oct 21
During a Market Mania, "no prudent professional is perceived to add value" - 24th Oct 21
Stock Market S&P500 Rallies Above $4400 – May Attempt To Advance To $4750~$4800 - 24th Oct 21
Inflation and the Crazy Crypto Markets - 23rd Oct 21
Easy PC Upgrades with Motherboard Combos - Overclockers UK Unboxing - MB, Memory and Ryzen 5600x CPU - 23rd Oct 21
Gold Mining Stocks Q3 2021 - 23rd Oct 21
Gold calmly continues cobbling its Handle, Miners lay in wait - 23rd Oct 21
US Economy Has Been in an Economic Depression Since 2008 - 22nd Oct 21
Extreme Ratios Point to Gold and Silver Price Readjustments - 22nd Oct 21
Bitcoin $100K or Ethereum $10K—which happens first? - 22nd Oct 21
This Isn’t Sci-Fi: How AI Is About To Disrupt This $11 Trillion Industry - 22nd Oct 21
Ravencoin RVN About to EXPLODE to NEW HIGHS! Last Chance to Buy Before it goes to the MOON! - 21st Oct 21
Stock Market Animal Spirits Returning - 21st Oct 21
Inflation Advances, and So Does Gold — Except That It Doesn’t - 21st Oct 21
Why A.I. Is About To Trigger The Next Great Medical Breakthrough - 21st Oct 21
Gold Price Slowly Going Nowhere - 20th Oct 21
Shocking Numbers Show Government Crowding Out Real Economy - 20th Oct 21
Crude Oil Is in the Fast Lane, But Where Is It Going? - 20th Oct 21
3 Tech Stocks That Could Change The World - 20th Oct 21
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21
How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
The Only way to Crush Inflation (not stocks) - 14th Oct 21
Why "Losses Are the Norm" in the Stock Market - 14th Oct 21
Sub Species Castle Maze at Alton Towers Scarefest 2021 - 14th Oct 21
Which Wallet is Best for Storing NFTs? - 14th Oct 21
Ailing UK Pound Has Global Effects - 14th Oct 21
How to Get 6 Years Life Out of Your Overclocked PC System, Optimum GPU, CPU and MB Performance - 13th Oct 21
The Demand Shock of 2022 - 12th Oct 21
4 Reasons Why NFTs Could Be The Future - 12th Oct 21
Crimex Silver: Murder Most Foul - 12th Oct 21
Bitcoin Rockets In Preparation For Liftoff To $100,000 - 12th Oct 21
INTEL Tech Stock to the MOON! INTC 2000 vs 2021 Market Bubble WARNING - 11th Oct 21
AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
Stock Market Wall of Worry Meets NFPs - 11th Oct 21
Stock Market Intermediate Correction Continues - 11th Oct 21
China / US Stock Markets Divergence - 10th Oct 21
Can US Save Taiwan From China? Taiwan Strait Naval Battle - PLA vs 7th Fleet War Game Simulation - 10th Oct 21
Gold Price Outlook: The Inflation Chasm Between Europe and the US - 10th Oct 21
US Real Estate ETFs React To Rising Housing Market Mortgage Interest Rates - 10th Oct 21
US China War over Taiwan Simulation 2021, Invasion Forecast - Who Will Win? - 9th Oct 21
When Will the Fed Taper? - 9th Oct 21
Dancing with Ghouls and Ghosts at Alton Towers Scarefest 2021 - 9th Oct 21
Stock Market FOMO Going into Crash Season - 8th Oct 21
Scan Computers - Custom Build PC 6 Months Later, Reliability, Issues, Quality of Tech Support Review - 8th Oct 21
Gold and Silver: Your Financial Main Battle Tanks - 8th Oct 21
How to handle the “Twin Crises” Evergrande and Debt Ceiling Threatening Stocks - 8th Oct 21
Why a Peak in US Home Prices May Be Approaching - 8th Oct 21
Alton Towers Scarefest is BACK! Post Pandemic Frights Begin, What it's Like to Enter Scarefest 2021 - 8th Oct 21
AJ Bell vs II Interactive Investor - Which Platform is Best for Buying US FAANG Stocks UK Investing - 7th Oct 21
Gold: Evergrande Investors' Savior - 7th Oct 21
Here's What Really Sets Interest Rates (Not Central Banks) - 7th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Highly Undervalued Biotechnology Stocks To Watch

Companies / BioTech Aug 28, 2019 - 06:45 AM GMT

By: Joshua_Rodriguez

Companies The biotechnology industry is an exciting one. As continued innovation drives a better scientific understanding of the human body and the ailments that weigh on it, we are seeing better outcomes for patients who are living longer, more fulfilling lives.

However, it’s not only the patients that are seeing tremendous benefit out of this innovation. Investors are benefiting greatly as well. After all, as new medications hit the market, tremendous revenue opportunities are being created for the companies creating these treatments.

Nonetheless, 2019 hasn’t been a great one for the biotechnology industry as a whole.

Nektar Therapeutics (NKTR): Beaten Down YTD But Creating A Compelling Opportunity

Nektar Therapeutics has had an incredibly rough year so far in 2019. Unfortunately, the stock has been cut nearly in half throughout the year. Nonetheless, it is showing incredible promise, and recent declines may be nothing more than a half-off discount.

Nektar Therapeutics is an immuno-oncology company. Their flagship candidate, known as NKTR-214, has the potential to treat several different types of cancer.

With regard to the development of the drug, Nektar Therapeutics partnered with Bristol-Myers Squibb (BMY) after the large pharma player made a $1.85 billion investment in Nektar back in 2018. As part of the deal, Nektar has the potential to receive up to $1.8 billion in milestone payments associated with NKTR-214.

At the moment, there’s a Phase 3 clinical program surrounding the drug in more than 20 indications involving 9 different types of cancer. Not to mention, with a strong focus on lung cancer, the company is addressing high-value indications.

Maybe that’s why analysts seem to be so impressed with the stock. According to Tip Ranks, the average price target on the stock is $40.80, suggesting an upside well over 100%. Even the most bearish of analysts give the stock a price target of $21.00, suggesting upside potential of more than 20%. All in all, the undervaluation here is clear!

AbbVie (ABBV): Tumbles In 2019 With A Strong Recovery Ahead

AbbVie is a massive player in the biotechnology space with a name that’s well known globally. Unfortunately, that name has slipped into the mud a bit in 2019, with year-to-date declines of more than 30%.

The company’s claim to fame is its Humira product. Unfortunately, it’s this product that’s leading to all of the concern. Humira currently generates about 61% of the revenue seen by AbbVie, creating a heavy dependence on the drug’s success.

In October of 2018, biosimilars to Humira found their way onto the European market. This competition has already begun to take part of Humira’s market share. Investors are also concerned about competition in AbbVie’s core market, the United States, as biosimilars have the greenlight to compete in 2023. 

I believe that the concerns with regard to competition are overblown. The truth of the matter is that AbbVie is working on multiple phase 3 clinical studies for a long line of existing drugs. These drugs are likely to see label expansions soon, giving the company more opportunities to expand revenue.

The company also has multiple new drugs in late stages of clinical development. Between two of these, risankizumab and upadacitinib, AbbVie said that it expects to reach revenues of $10 billion annually by 2025.

It’s also worth keeping in mind that the company has several drugs in blockbuster indications that have raked in great sales. Imbruvica, a cancer drug, and Mavyret, a hepatitis C virus drug, are both generating strong revenues.

Although concerns about Humira are rising, investors can’t deny the 16% year-over-year growth in revenue seen in 2018, nor the adjusted EPS growth of 41%. With a market acting on fear and an opportunity that should elicit greed, I believe that AbbVie is primed for strong growth ahead.

Spherix (SPEX): A Small Company With Dynamite Potential

Spherix is by far the smallest company on this list, but it’s definitely not the smallest opportunity. At the moment, the company primarily acts as a hedge fund, making investments in biotechnology companies and reaping the rewards of their growth.

Interestingly, the argument that Spherix is undervalued is very easy to make. Just take a look at the company’s market cap and the book value of the company’s assets. When you do, you’ll see that the company trades on a market cap that represents less than half of the value of its assets.

The book value has seen dramatic growth in recent years. These gains have largely been due to an investment made in Hoth Therapeutics worth about $700,000. Today Hoth Therapeutics is a NASDAQ listed company worth around $50 million. The original ~$700,000 investment is now worth more than $10 million.

The company also made a relatively large investment in CBM recently, purchasing a 20% stake in the oncology-focused biotechnology company. Moving forward, Spherix intends to acquire CBM Biopharma, with a vote expected to take place early next month to decide the fate of the deal.

It’s also worth mentioning that the company recently proposed a dividend worth about $500,000 and intends on proposing more down the road. This is something that you don’t see companies of this stage doing, making it that much more of an eye catcher.

Should all go well, Spherix would immediately become a development-stage biotechnology company with plenty of cash to get through several catalysts. Moreover, considering the fact that the stock has lost nearly a third of its value this year, the opportunity is heavily discounted, making this stock one that’s hard to ignore.

Ligand Pharmaceuticals (LGND): Looked At As Speculative; In Reality, Anything But

Ligand Pharmaceuticals is another stock that has had a pretty rough year. Year to date, the stock has lost nearly a third of its value as analysts largely pass it off as a speculative investment. When you dig into the opportunity, you’ll likely find that it’s anything but.

In my view a large part of the value in Ligand Pharmaceuticals is its business model. While it is a biotechnology company, the company doesn’t actually develop drugs. Well, at least, it doesn’t do it on its own.

The company is focused on developing platforms and licensing them out to drugmakers. These platforms essentially help developers producer new treatments more effectively.

At the moment, Ligand’s technologies are used in 10 different products on the market, inclusive of products from very big names. These technologies are found in Kyprolis by Amgen (AMGN) and Promacta by Novartis (NVS).

To put an end to the speculation conversation, just take a look at the company’s revenues. In 2018, the company generated 78% year-over-year growth. EPS was up more than 10 times on a year-over-year basis.

Moving forward, there are several opportunities to watch for. The company’s technologies are used in 8 late-stage candidates, 21 Phase 2 candidates, and 24 phase 1 candidates. Any positive news out of any of these may act as positive catalysts ahead.

While Ligand has taken a beating so far this year, the stock seems to be doing nothing more than presenting a discount on long-run growth.

Aerie Pharmaceuticals (AERI): Rocklatan Could Quickly Become A Blockbuster

Aerie Pharmaceuticals is another stock that has felt quite a bit of pain this year. The stock is down by almost 40% year to date, but again, this may prove to be a strong opportunity.

Recently, Aerie Pharmaceuticals has announced the regulatory approval of two different treatments; Rhopress was launched in 2018 and Rocklatan was approved in early 2019.

Although Rhopress had a strong start in 2018, the most valuable of these two drugs is Rocklatan, in my view. Indicated as a potential option for patients with glaucoma, the treatment has limited competition in the space.

Considering a strong start with the company’s first drug, Rhopressa, I’m expecting to see more of the same with Rocklatan in an indication that offers up a larger opportunity.

In my view, once sales reports start to show growth in Rocklatan revenues, the stock will start to find its way back up to a more realistic valuation. This is likely why analysts followed by Tip Ranks suggest a potential to see 200% gains based on average price target. All in all, Aerie Pharmaceuticals is a stock that’s well worth watching.

Final Thoughts

While the stocks listed above have lagged behind their peers in the biotech space, I believe that they each represent a strong opportunity. Due to a rough year in 2019, these stocks are trading at incredible discounts. Based on the assets they possess, these discounts shouldn’t last long!

This article is a paid advertisement. View all relevant disclosures here.

By Joshua Rodriguez

© 2019 Copyright Joshua Rodriguez - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in